{
  "pmcid": "5830087",
  "config": {
    "model": "gemini",
    "strategy": "few-shot"
  },
  "usage": {
    "input": 20289,
    "output": 963
  },
  "raw_text": "{\n  \"extractions\": [\n    {\n      \"outcome\": \"objective response rate (ORR)\",\n      \"intervention\": \"BTH1677 arm ( intravenous [IV] BTH1677, 4 mg/kg, weekly; IV bevacizumab, 15 mg/kg, once each 3-week cycle [Q3W]; IV carboplatin, 6 mg/mL/min Calvert formula area-under-the-curve, Q3W; and IV paclitaxel, 200 mg/m2, Q3W)\",\n      \"comparator\": \"Control arm ( bevacizumab/carboplatin/paclitaxel as above)\",\n      \"outcome_type\": \"binary\",\n      \"intervention_events\": 29,\n      \"intervention_group_size\": 48,\n      \"comparator_events\": 10,\n      \"comparator_group_size\": 23,\n      \"intervention_mean\": null,\n      \"intervention_standard_deviation\": null,\n      \"comparator_mean\": null,\n      \"comparator_standard_deviation\": null\n    },\n    {\n      \"outcome\": \"disease control rate\",\n      \"intervention\": \"BTH1677 arm ( intravenous [IV] BTH1677, 4 mg/kg, weekly; IV bevacizumab, 15 mg/kg, once each 3-week cycle [Q3W]; IV carboplatin, 6 mg/mL/min Calvert formula area-under-the-curve, Q3W; and IV paclitaxel, 200 mg/m2, Q3W)\",\n      \"comparator\": \"Control arm ( bevacizumab/carboplatin/paclitaxel as above)\",\n      \"outcome_type\": \"binary\",\n      \"intervention_events\": 45,\n      \"intervention_group_size\": 48,\n      \"comparator_events\": 21,\n      \"comparator_group_size\": 23,\n      \"intervention_mean\": null,\n      \"intervention_standard_deviation\": null,\n      \"comparator_mean\": null,\n      \"comparator_standard_deviation\": null\n    },\n    {\n      \"outcome\": \"duration of objective response\",\n      \"intervention\": \"BTH1677 arm ( intravenous [IV] BTH1677, 4 mg/kg, weekly; IV bevacizumab, 15 mg/kg, once each 3-week cycle [Q3W]; IV carboplatin, 6 mg/mL/min Calvert formula area-under-the-curve, Q3W; and IV paclitaxel, 200 mg/m2, Q3W)\",\n      \"comparator\": \"Control arm ( bevacizumab/carboplatin/paclitaxel as above)\",\n      \"outcome_type\": \"continuous\",\n      \"intervention_events\": null,\n      \"intervention_group_size\": 29,\n      \"comparator_events\": null,\n      \"comparator_group_size\": 10,\n      \"intervention_mean\": null,\n      \"intervention_standard_deviation\": null,\n      \"comparator_mean\": null,\n      \"comparator_standard_deviation\": null\n    },\n    {\n      \"outcome\": \"progression-free survival\",\n      \"intervention\": \"BTH1677 arm ( intravenous [IV] BTH1677, 4 mg/kg, weekly; IV bevacizumab, 15 mg/kg, once each 3-week cycle [Q3W]; IV carboplatin, 6 mg/mL/min Calvert formula area-under-the-curve, Q3W; and IV paclitaxel, 200 mg/m2, Q3W)\",\n      \"comparator\": \"Control arm ( bevacizumab/carboplatin/paclitaxel as above)\",\n      \"outcome_type\": \"continuous\",\n      \"intervention_events\": null,\n      \"intervention_group_size\": 50,\n      \"comparator_events\": null,\n      \"comparator_group_size\": 23,\n      \"intervention_mean\": null,\n      \"intervention_standard_deviation\": null,\n      \"comparator_mean\": null,\n      \"comparator_standard_deviation\": null\n    }\n  ]\n}",
  "extraction": [
    {
      "outcome": "objective response rate (ORR)",
      "intervention": "BTH1677 arm ( intravenous [IV] BTH1677, 4 mg/kg, weekly; IV bevacizumab, 15 mg/kg, once each 3-week cycle [Q3W]; IV carboplatin, 6 mg/mL/min Calvert formula area-under-the-curve, Q3W; and IV paclitaxel, 200 mg/m2, Q3W)",
      "comparator": "Control arm ( bevacizumab/carboplatin/paclitaxel as above)",
      "outcome_type": "binary",
      "intervention_events": 29,
      "intervention_group_size": 48,
      "comparator_events": 10,
      "comparator_group_size": 23,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "5830087"
    },
    {
      "outcome": "disease control rate",
      "intervention": "BTH1677 arm ( intravenous [IV] BTH1677, 4 mg/kg, weekly; IV bevacizumab, 15 mg/kg, once each 3-week cycle [Q3W]; IV carboplatin, 6 mg/mL/min Calvert formula area-under-the-curve, Q3W; and IV paclitaxel, 200 mg/m2, Q3W)",
      "comparator": "Control arm ( bevacizumab/carboplatin/paclitaxel as above)",
      "outcome_type": "binary",
      "intervention_events": 45,
      "intervention_group_size": 48,
      "comparator_events": 21,
      "comparator_group_size": 23,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "5830087"
    },
    {
      "outcome": "duration of objective response",
      "intervention": "BTH1677 arm ( intravenous [IV] BTH1677, 4 mg/kg, weekly; IV bevacizumab, 15 mg/kg, once each 3-week cycle [Q3W]; IV carboplatin, 6 mg/mL/min Calvert formula area-under-the-curve, Q3W; and IV paclitaxel, 200 mg/m2, Q3W)",
      "comparator": "Control arm ( bevacizumab/carboplatin/paclitaxel as above)",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": 29,
      "comparator_events": null,
      "comparator_group_size": 10,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "5830087"
    },
    {
      "outcome": "progression-free survival",
      "intervention": "BTH1677 arm ( intravenous [IV] BTH1677, 4 mg/kg, weekly; IV bevacizumab, 15 mg/kg, once each 3-week cycle [Q3W]; IV carboplatin, 6 mg/mL/min Calvert formula area-under-the-curve, Q3W; and IV paclitaxel, 200 mg/m2, Q3W)",
      "comparator": "Control arm ( bevacizumab/carboplatin/paclitaxel as above)",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": 50,
      "comparator_events": null,
      "comparator_group_size": 23,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "5830087"
    }
  ]
}